B+
Bull case
25%
Probability
Target price
$22.00
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
IART
Integra LifeSciencesANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The Q2 print showed adjusted EPS of $0.56 versus $0.45 a year earlier, adjusted EBITDA margin expansion to 18.7%, improving supply reliability, and a planned SurgiMend relaunch. These support a cautious recovery case, but the stored consensus-beat and revision evidence is secondary and analyst coverage is incomplete.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +10.6.
What can break
2026 reported revenue guidance was updated for stronger U.S. dollar effects, while underlying organic growth guidance remains low. [#SEC-8K-2026-07-29]
Momentum
31
Value
59
Sentiment
82
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $19.56 · Bull $22.00 · Bear $13.50Analysis 2026-09-09; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $19.56
Why
Momentum31 · Δ7d +7.1
Value59 · Δ7d -0.0
Sentiment82 · Δ7d +10.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +10.6.
Contradictions & invalidation
- • 2026 reported revenue guidance was updated for stronger U.S. dollar effects, while underlying organic growth guidance remains low. [#SEC-8K-2026-07-29]
- • Analyst target count, rating changes, and detailed post-earnings estimate revisions are not available in the packet, limiting confidence in the valuation signal.
- • Revenue growth remains modest, Tissue Reconstruction declined 2.0% organically, ENT declined 1.9% with reimbursement pressure, and the post-print context reports roughly a 1.6% share-price decline plus downward estimate-review momentum.
Catalyst clock
2026-12-08
Planned fourth-quarter SurgiMend relaunch
Lead driver: Sentiment · See AI snapshot
Momentum
31
9% active weight
Current posture
7d trendImproving
Δ7d
+7.1
Δ21d
-31.2
Value
59
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+1.7
Sentiment
82
62% active weight
Current posture
7d trendImproving
Δ7d
+10.6
Δ21d
+13.1
Why this grade
Composite grade A. Momentum 30.7 / Value 59.1 / Sentiment 81.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-09. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$19.56
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$13.50
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.37B
Beta
1.04
Shares Out
77.77M
P/E (TTM) · Derived
-2.6
P/S (TTM)
0.60
P/FCF (TTM)
65.17
Rev YoY
+0.8%
EPS YoY
-100.9%
Gross Margin
+55.2%
Op Margin
+10.7%
Net Debt
$1.77B
Current Ratio
3.60
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data